Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? [electronic resource]
Producer: 20200331Description: 39 p. digitalISSN:- 2051-1426
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents, Immunological -- therapeutic use
- Female
- Humans
- Immunotherapy
- Ipilimumab -- therapeutic use
- Male
- Melanoma -- drug therapy
- Middle Aged
- Skin Neoplasms -- drug therapy
- Survival Analysis
- Treatment Outcome
- Tumor Burden -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.